
Jana Ruda-Kucerova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3279435/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Health safety issues of synthetic food colorants. Regulatory Toxicology and Pharmacology, 2015, 73, 914-922.	2.7	359
2	Anticancer Activity of Artemisinin and its Derivatives. Anticancer Research, 2017, 37, 5995-6003.	1.1	104
3	Principles of diffusion kurtosis imaging and its role in early diagnosis of neurodegenerative disorders. Brain Research Bulletin, 2018, 139, 91-98.	3.0	72
4	Sex Differences in the Reinstatement of Methamphetamine Seeking after Forced Abstinence in Sprague-Dawley Rats. Frontiers in Psychiatry, 2015, 6, 91.	2.6	64
5	HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophreniaâ€like animals. Journal of Cellular Physiology, 2018, 233, 530-548.	4.1	61
6	Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology, 2019, 146, 212-221.	4.1	59
7	Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Patents on CNS Drug Discovery, 2014, 9, 13-25.	0.9	57
8	Leading compounds for the validation of animal models of psychopathology. Cell and Tissue Research, 2013, 354, 309-330.	2.9	53
9	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacological Research, 2021, 164, 105357.	7.1	43
10	The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 208-214.	0.6	38
11	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	4.4	36
12	Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats. World Journal of Biological Psychiatry, 2017, 18, 129-142.	2.6	33
13	Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Frontiers in Pharmacology, 2014, 5, 44.	3.5	32
14	The effects of methamphetamine self-administration on behavioural sensitization in the olfactory bulbectomy rat model of depression. International Journal of Neuropsychopharmacology, 2012, 15, 1503-1511.	2.1	28
15	Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats. Psychoneuroendocrinology, 2016, 73, 177-185.	2.7	28
16	Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging. Brain, Behavior, and Immunity, 2017, 61, 197-208.	4.1	28
17	Different effects of prenatal MAM vs. perinatal THC exposure on regional cerebral blood perfusion detected by Arterial Spin Labelling MRI in rats. Scientific Reports, 2019, 9, 6062.	3.3	26
18	Low Vs. High Alcohol: Central Benefits Vs. Detriments. Neurotoxicity Research, 2018, 34, 860-869.	2.7	24

Jana Ruda-Kucerova

#	Article	IF	CITATIONS
19	Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats Experimental and Clinical Psychopharmacology, 2017, 25, 84-93.	1.8	23
20	Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence. , 2015, , 97-129.		22
21	Reward related neurotransmitter changes in a model of depression: An in vivo microdialysis study. World Journal of Biological Psychiatry, 2015, 16, 521-535.	2.6	22
22	Both ketamine and NBQX attenuate alcohol drinking in male Wistar rats. Neuroscience Letters, 2018, 666, 175-180.	2.1	21
23	Poly(I:C) model of schizophrenia in rats induces sex-dependent functional brain changes detected by MRI that are not reversed by aripiprazole treatment. Brain Research Bulletin, 2018, 137, 146-155.	3.0	21
24	Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia. Neurotoxicity Research, 2017, 32, 121-133.	2.7	19
25	Lateâ€stage αâ€synuclein accumulation in TNWTâ€61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging. Journal of Neurochemistry, 2016, 136, 1259-1269.	3.9	18
26	Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study. Neurotoxicity Research, 2015, 28, 281-289.	2.7	17
27	Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. Neuropharmacology, 2017, 123, 148-158.	4.1	16
28	Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's Disease. Neurotoxicity Research, 2019, 36, 724-735.	2.7	12
29	Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation. Toxicology and Applied Pharmacology, 2020, 406, 115214.	2.8	12
30	Diffusion kurtosis imaging detects the timeâ€dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease. Journal of Neurochemistry, 2021, 158, 779-797.	3.9	12
31	Depot risperidone-induced adverse metabolic alterations in female rats. Journal of Psychopharmacology, 2017, 31, 487-499.	4.0	11
32	Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110165.	4.8	10
33	Olfactory bulbectomy increases reinstatement of methamphetamine seeking after a forced abstinence in rats. Behavioural Brain Research, 2016, 297, 20-27.	2.2	9
34	Effects of low-dose alcohol exposure in adolescence on subsequent alcohol drinking in adulthood in a rat model of depression. World Journal of Biological Psychiatry, 2021, 22, 757-769.	2.6	9
35	Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules, 2022, 12, 108.	4.0	9
36	Improved Pharmacokinetics and Tissue Uptake of Complexed Daidzein in Rats. Pharmaceutics, 2020, 12, 162.	4.5	8

Jana Ruda-Kucerova

#	Article	IF	CITATIONS
37	Prenatal exposure to modafinil alters behavioural response to methamphetamine in adult male mice. International Journal of Developmental Neuroscience, 2018, 67, 37-45.	1.6	7
38	Sex and Feeding Status Differently Affect Natural Reward Seeking Behavior in Olfactory Bulbectomized Rats. Frontiers in Behavioral Neuroscience, 2018, 12, 255.	2.0	7
39	Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats. Pharmacological Reports, 2019, 71, 839-847.	3.3	6
40	Oral administration of BDNF and/or GDNF normalizes serum BDNF level in the olfactory bulbectomized rats: A proof of concept study. Pharmacological Reports, 2019, 71, 669-675.	3.3	5
41	NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats. World Journal of Biological Psychiatry, 2021, 22, 733-743.	2.6	5
42	PRENATAL EXPOSURE TO MODAFINIL ALTERS LOCOMOTOR BEHAVIOUR AND LEUCOCYTE PHAGOCYTOSIS IN MICE. Psychiatria Danubina, 0, 30, 356-366.	0.4	2
43	Olfactory Bulbectomy in Methamphetamine-Treated Rat Mothers Induces Impairment in Somatic and Functional Development of Their Offspring. Physiological Research, 2017, 66, S469-S479.	0.9	2
44	Depressive-like phenotype enhances relapse of nicotine seeking after forced abstinence in rats. World Journal of Biological Psychiatry, 2023, 24, 46-57.	2.6	2
45	P.6.d.011 Gender differences in effects of MDMA, cannabinoid agonist and their combinations in mice. European Neuropsychopharmacology, 2006, 16, S512-S513.	0.7	0
46	P.4.06 Aripiprazole impact on methamphetamine i.v. self-administration in the olfactory-bulbectomy model of depression in rats. European Neuropsychopharmacology, 2009, 19, S84-S85.	0.7	0
47	P.3.a.005 Structural and behavioural changes in a rodent developmental disruption model of schizophrenia. European Neuropsychopharmacology, 2014, 24, S486.	0.7	0
48	Sex differences in a neurodevelopmental animal model of schizophrenia: focus on white matter structures and myelin. European Neuropsychopharmacology, 2017, 27, S890-S891.	0.7	0
49	Peripubertal treatment with cannabidiol reverses behavioral alterations in â^†9-THC animal model of schizophrenia. European Neuropsychopharmacology, 2019, 29, S257-S258.	0.7	0
50	Validation of Diffusion Kurtosis as an Early-Stage Biomarker of Parkinson's in Animal Models. Neuromethods, 2022, , 429-455.	0.3	0
51	Effectiveness of marigold (Calendula officinalis, L.) in dermatology. Praktické LékárenstvÃ , 2017, 13, e36-e41.	0.1	Ο